Spironolactone
Hyperkalemia
Hospital de Messejana Dr. Carlos Alberto Studart GomesSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Hyperkalemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Finerenone Hospital de Messejana Dr. Carlos Alberto Studart Gomes | Phase 4 | B |
Urea University of California, San Francisco | Phase 1/2 | CCC |
Same molecule, other indications
Spironolactone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →